Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.
暂无分享,去创建一个
C. Klein | D. Lazarević | C. Ries | A. Corti | G. Simonetti | Davide Cittaro | N. Van Rooijen | A. Anselmo | Michele De Palma | M. Ponzoni | T. Rodriguez | M. Riba | P. Ghia | L. Scarfò | C. Scielzo | M. Rocchi | M. T. Bertilaccio | Federica Barbaglio | G. Galletti | P. Ranghetti | Martina Rocchi | F. Caligaris‐cappio | Carola H. Ries
[1] G. Marti,et al. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy , 2015, Clinical Cancer Research.
[2] Brian Ruffell,et al. Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.
[3] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[4] J. Blay,et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.
[5] J. Cayuela,et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.
[6] P. L. Bergsagel,et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. , 2014, Blood.
[7] D. Rossi,et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia , 2014, Leukemia.
[8] G. Juliusson,et al. On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort , 2014, Leukemia.
[9] F. caligaris-Cappio,et al. How the microenvironment wires the natural history of chronic lymphocytic leukemia. , 2014, Seminars in cancer biology.
[10] J. Gribben,et al. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. , 2014, Seminars in cancer biology.
[11] Jae-seok Roe,et al. C/EBPα: critical at the origin of leukemic transformation , 2014, The Journal of experimental medicine.
[12] C. Klein,et al. Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy , 2013, The Journal of Immunology.
[13] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[14] L. Monti,et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis , 2013, Proceedings of the National Academy of Sciences.
[15] A. Filip,et al. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? , 2013, Blood cells, molecules & diseases.
[16] C. Lewis,et al. Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.
[17] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[18] G. Fingerle-Rowson,et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. , 2013, Blood.
[19] A. Kohlmann,et al. Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo , 2013, Cancer cell.
[20] Zhi-ren Zhang,et al. Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.
[21] L. Pasqualucci,et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.
[22] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[23] L. Pasqualucci,et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.
[24] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[25] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[26] A. Sica,et al. Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase , 2010, Proceedings of the National Academy of Sciences.
[27] D. Hume,et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. , 2010, Blood.
[28] C. Klein,et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.
[29] G. Simonetti,et al. A novel Rag2-/-gammac-/--xenograft model of human CLL. , 2010, Blood.
[30] G. Kroemer,et al. AIF: Not Just an Apoptosis‐Inducing Factor , 2009, Annals of the New York Academy of Sciences.
[31] Hiroyuki Aburatani,et al. The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase , 2008, Nature Cell Biology.
[32] P. Ghia,et al. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Rosenwald,et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. , 2007, Blood.
[34] M. Keating,et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.
[35] Stefano Volinia,et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. , 2006, Cancer research.
[36] Silvano Sozzani,et al. The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.
[37] N. Van Rooijen,et al. Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.
[38] Jiayou Zhang,et al. Conditional macrophage ablation in transgenic mice expressing a Fas‐based suicide gene , 2004, Journal of leukocyte biology.
[39] M. Fey,et al. Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL) , 2003, British journal of haematology.
[40] C. Croce,et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[41] T. Kipps,et al. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. , 2002, Blood.
[42] H. Deeg,et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study , 2002, Leukemia.
[43] N Tsukada,et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.
[44] N. Van Rooijen,et al. Liposomes for specific depletion of macrophages from organs and tissues. , 2010, Methods in molecular biology.
[45] H. Döhner,et al. From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.
[46] F. Batista,et al. The who, how and where of antigen presentation to B cells , 2009, Nature Reviews Immunology.
[47] W. Digel,et al. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. , 1990, Blood.